Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Research Grants 1 show all


$106K
2005

Patents 35show all

  • 7
    A61K - Preparations for medical, dental, or toilet purposes
  • 4
    Y02A - Technologies for adaptation to climate change
  • 3
    C07B - General methods of organic chemistry
  • 3
    C07C - Acyclic or carbocyclic compounds

Clinical Trials 12show all

6Phase 24Phase 1/Phase 22Phase 1

SEC Filings show all


1
D

Contact Information

101 Lindenwood Drive Suite 405
Malvern, PA 19355
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$87,800,18051-1002010-02-06Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2007-04-10$50,000,000Series CPerseusEnterprise Partners, Sofinnova Investments, Domain Associates
2004-11-01$30,000,000Series B$45,400,000Scale Venture PartnersDomain Associates, Sofinnova Investments, U.S. Venture Partners (USVP), Enterprise Partners
2010-02-06$1,800,180Debt Financing
2003-01-01$6,000,000Series A$8,650,000

SEC Form D Funding Events

DateOfferedSoldType
2010-02-05$15,001,500$1,800,180Debt, Option to Acquire

Key Executives

  • J. Mel Sorensen
    Executive Officer, Director
  • Louis Bock
    Director
  • Michael Powell
    Executive Officer, Director
  • Marc Lippman
    Director
  • Joel Sussman
    Executive Officer, Director
  • Norman Selby
    Director
  • Andrew E. Senyei
    Director
  • Eckard Weber
    Director